Another positive development for Lilly's weight-loss portfolio, with the company reporting positive results from its Phase 3 trial of a once-daily oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
Lilly records another win in weight loss in trial of oral GLP-1 agonist
April 22, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - Series 5. Ep.30
August 28, 2026 - - Podcast -
Sandoz earns workplace recognition amid push for medicine access
August 28, 2026 - - Latest News -
Cheaper medicines save Australians $1.4 billion as pharmacists urge freeze for all patients
August 28, 2026 - - Latest News -
Mayne Pharma bets on women’s health and direct distribution after a difficult year
August 28, 2026 - - Latest News -
Patients Australia puts healthcare’s quiet achievers in the spotlight
August 28, 2026 - - Latest News -
Weight loss medicines drive revenue growth for Sigma and Wesfarmers Health
August 28, 2026 - - BioPharma -
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News
